Anonymous11 days ago
A growing body of observational research links GLP-1 receptor agonist drugs like semaglutide and tirzepatide to reduced cancer risk and improved survival across multiple tumor types, with relative risk reductions ranging from 17% for overall cancer incidence to 59% for pancreatic cancer. However, independent methodologists have identified serious biases in nearly all major studies, no randomized trial has tested cancer prevention as a primary endpoint, and the drugs' cost — roughly $900 to $1,300 per month — raises steep questions about whether preventive prescribing could ever be cost-effective at scale.